Octapharma AG

A major area of interest is the control of perioperative bleeding and the maintenance of haemostatic efficacy in patients undergoing complex procedures. Research includes treatment support for individuals with inherited bleeding disorders and those requiring urgent surgical care.

• Major surgery
• Cardiac surgery
• Emergency haemostasis

Clinical work in this area spans patients with haemophilia A, including women and girls, as well as individuals managed with factor VIII-based support in operative settings.

Octapharma AG also pursues research in the management of acute major bleeding associated with direct oral anticoagulants, particularly therapies targeting factor Xa inhibition. This reflects a focus on urgent reversal strategies in high-risk bleeding situations.

• DOAC-associated bleeding
• Factor Xa inhibitor reversal
• Prothrombin complex concentrate

These studies are centred on restoring effective haemostasis in patients requiring immediate control of bleeding complications.

The sponsor maintains a clear therapeutic interest in haemophilia A, including perioperative care in patients receiving emicizumab prophylaxis and in female patients with inherited bleeding disorders. The research landscape extends to populations with distinct clinical needs and surgical challenges.

• Severe haemophilia A
• Women and girls with haemophilia A
• Perioperative factor VIII support

These trials highlight attention to individualised haemostatic care across diverse patient groups requiring specialised bleeding management.